Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial

被引:0
作者
Verma, S. [1 ]
Leiter, L. A. [2 ]
Mazer, C. D. [2 ]
Bain, S. C. [3 ]
Buse, J. [4 ]
Marso, S. [5 ]
Nauck, M. [6 ]
Zinman, B. [2 ]
Bosch-Traberg, H. [7 ]
Frimer-Larsen, H. [7 ]
Michelsen, M. M. [7 ]
Bhatt, D. L. [8 ]
机构
[1] St Michaels Hosp, Cardiac Surg, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Swansea Univ, Swansea, W Glam, Wales
[4] Univ North Carolina Hosp, Chapel Hill, NC USA
[5] HCA Midwest Hlth Heart & Vasc Inst, Kansas City, MO USA
[6] RUB, Bochum, Germany
[7] Novo Nordisk AS, Soborg, Denmark
[8] Harvard Med Sch, Boston, MA 02115 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P2858
引用
收藏
页码:598 / 598
页数:1
相关论文
empty
未找到相关数据